Arrowhead Drug Patent Portfolio
Arrowhead owns 1 orange book drug protected by 5 US patents Given below is the list of Arrowhead's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10597657 | Rnai Agents And Compositions For Inhibiting Expression Of Apolipoprotein C-Iii (Apoc3) | 10 Sep, 2038 | Active |
| US11214801 | Rnai Agents And Compositions For Inhibiting Expression Of Apolipoprotein C-Iii (Apoc3) | 10 Sep, 2038 | Active |
| US12365899 | Rnai Agents And Compositions For Inhibiting Expression Of Apolipoprotein C-Iii (Apoc3) | 10 Sep, 2038 | Active |
| US10294474 | Targeting Ligands | 07 Mar, 2037 | Active |
| US11174481 | Targeting Ligands | 07 Mar, 2037 | Active |
Latest Legal Activities on Arrowhead's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Arrowhead.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Recordation of Patent Grant Mailed | 29 Jul, 2025 | US12365899 |
| Email Notification | 23 Jul, 2025 | US12365899 |
| Recordation of Patent eGrant | 22 Jul, 2025 | US12365899 |
| Mail Patent eGrant Notification | 22 Jul, 2025 | US12365899 |
| Patent eGrant Notification | 22 Jul, 2025 | US12365899 |
| Patent Issue Date Used in PTA Calculation | 22 Jul, 2025 | US12365899 |
| Email Notification | 10 Jul, 2025 | US12365899 |
| Issue Notification Mailed | 09 Jul, 2025 | US12365899 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 26 Jun, 2025 | US11214801 |
| Dispatch to FDC | 19 Jun, 2025 | US12365899 |
| Application Is Considered Ready for Issue | 19 Jun, 2025 | US12365899 |
| Issue Fee Payment Received | 18 Jun, 2025 | US12365899 |
| Issue Fee Payment Verified | 18 Jun, 2025 | US12365899 |
| Correspondence Address Change | 13 May, 2025 | US11174481 |
| Correspondence Address Change | 13 May, 2025 | US10294474 |
Arrowhead's Family Patents
Arrowhead Drug List
Given below is the complete list of Arrowhead's drugs and the patents protecting them.
1. Redemplo
Redemplo is protected by 5 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10597657 | Rnai Agents And Compositions For Inhibiting Expression Of Apolipoprotein C-Iii (Apoc3) |
10 Sep, 2038
(12 years from now)
| Active |
| US11214801 | Rnai Agents And Compositions For Inhibiting Expression Of Apolipoprotein C-Iii (Apoc3) |
10 Sep, 2038
(12 years from now)
| Active |
| US12365899 | Rnai Agents And Compositions For Inhibiting Expression Of Apolipoprotein C-Iii (Apoc3) |
10 Sep, 2038
(12 years from now)
| Active |
| US10294474 | Targeting Ligands |
07 Mar, 2037
(10 years from now)
| Active |
| US11174481 | Targeting Ligands |
07 Mar, 2037
(10 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Redemplo's drug page